As filed with the Securities and Exchange Commission on February 6, 2026 Registration No. 333-292741 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Faraday Future Intelligent Electric Inc. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 3711 | 84-4720320 | | --- | --- | --- | | (State or Other Jurisdiction of | (Primary standard industrial | (I.R.S. Employer | | Incorporation or O ...

As filed with the Securities and Exchange Commission on January 14, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Faraday Future Intelligent Electric Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organization) (Primary standard industrial Delaware 3711 84-4720320 (I.R.S. Employer Identification No.) 18455 S. Figueroa Street Garde ...

Core Insights - AIxCrypto Inc. has appointed Andrew Grossman as Head of Legal to oversee legal, compliance, and governance functions, focusing on SEC disclosures and strategic agreements [1][2][3] - The company recently rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc., aiming to integrate AI and blockchain technologies while bridging Web2 and Web3 [4][5] Company Strategy - AIxCrypto is positioned at the intersection of Web3 and AI, with a commitment to responsible innovation and sustainable commercial value [3] - The company aims to create a leading ecosystem that connects AI, crypto, and blockchain technologies, establishing itself as a gateway to the emerging AI Web3 landscape [4][5] Leadership and Compliance - Andrew Grossman brings extensive experience in securities regulation and corporate governance, which will enhance AIxCrypto's compliance framework [2][3] - His leadership is expected to strengthen the company's compliance capabilities and support long-term regulatory alignment, particularly in collaboration with Faraday Future Intelligent Electric, Inc. [3]

Core Insights - Faraday Future Intelligent Electric Inc. (FF) is making significant progress in its business operations, particularly with the FX Super One vehicle and its strategic investments in QLGN, which will be rebranded as AIxCrypto [1][5][12] Group 1: Business Developments - FF signed a non-binding pre-order agreement for 100 units of the FX Super One with the California Hanlin Entrepreneurs Association, receiving a $10,000 non-refundable deposit, indicating strong demand from business leaders [3] - The first batch of complete FX Super One parts has departed from Shanghai and is expected to arrive in Long Beach by the end of November, marking the start of the pre-production trial-build phase [6] - FF and FX vehicles will adopt the North American Charging System (NACS), gaining access to over 28,000 Tesla Superchargers, enhancing infrastructure for future drivers [4][5] Group 2: Financial Performance - In Q3, FF reported a total loss of approximately $206 million, with a one-time impairment of about $138 million due to asset realignment, resulting in an operating loss of $68 million [7] - Despite the losses, FF achieved financing inflow greater than operating outflow for the sixth consecutive quarter, ending Q3 with the highest cash balance in nearly two years [8] Group 3: Strategic Initiatives - FF will officially deliver the FX Super One to its first global owner, Andrés Iniesta, on November 27, 2025, marking the launch of the EAI MPV era in the UAE market [9] - The company plans to participate in the Los Angeles Auto Show, showcasing its First Class EAI-MPV to the public [4][12] Group 4: Corporate Governance - FF is set to become the majority and controlling stockholder of QLGN, with an initial ownership of about 55%, which will enhance its governance and strategic capabilities [5] - The complexity of preparing consolidated financial statements for two public companies has increased, leading to a slight delay in the disclosure schedule [10]

Core Insights - Qualigen Therapeutics, Inc. is undergoing a significant transformation, transitioning from a traditional biotechnology company to a decentralized artificial intelligence technology platform under the new name AIxCrypto Holdings, Inc. [4][5][6] - Faraday Future is set to become the majority and controlling shareholder with an estimated 55% direct equity ownership, increasing to approximately 63% when including affiliated stockholders [2][10] - The company will host a renaming and ticker activation ceremony on November 20, 2025, where it will unveil its new business framework, ecosystem architecture, and a three-year development roadmap [4][7][10] Shareholder Approvals - All proposals at the Special Meeting of Stockholders were approved, confirming Faraday Future as the new majority and controlling shareholder [10] - The approved actions include the nomination of a majority of board seats by Faraday Future prior to the renaming event [10] - A subscription agreement was approved for the issuance of 337,432 common shares and 39,943 Series B convertible preferred shares [11] Strategic Transformation - The renaming signifies a strategic shift towards a Web3-driven decentralized AI technology platform, aiming to create a reciprocal strategic enablement dynamic between AIxCrypto and Faraday Future [5][6] - The company is committed to defining itself as a leading gateway to the AI × Web3 era, with a focus on decentralized AI, Web3 asset infrastructure, and intelligent trading systems [6][7][8] - The upcoming ceremony will also introduce the newly structured Board of Directors and the incoming Chairperson [4][10]

Core Insights - Faraday Future Intelligent Electric Inc. reported its financial results for Q3 2025, highlighting operational execution, financial position, and outlook for Q4 2025 and 2026 [1][12] Q3 Performance Summary - The company launched the FX Super One MPV on July 17, 2025, securing over 11,000 non-binding pre-orders since the event [3] - FX Super One has entered pre-production at the Hanford manufacturing facility, with the first vehicle expected to roll off the line soon [4][5] - The FX Super One was launched in the UAE on October 28, 2025, with a price point of approximately $85,000 and initial deliveries planned for November [9][10] Financial Highlights - The company secured $136 million in financing commitments, with $82 million received by the end of Q3 2025 [13] - Loss from operations was $206.8 million for the three months ending September 30, 2025, primarily due to investments in engineering and strategic initiatives [13] - Financing cash inflow for the nine months ended September 30, 2025, was $135.8 million, a 144% increase from the previous year [13] Strategic Developments - Faraday Future made a strategic investment of approximately $41 million in Qualigen Therapeutics to enhance its AI technology capabilities [8][17] - The company is focused on building a robust internal R&D capability in software and AI, while transferring core technologies from the FF 91 to the FX product line [20] - FX has established FX Pars in several states, with plans for expansion to New Jersey, Florida, and Washington [19] Future Outlook - The company is on track to deliver additional FF 91 units in December 2025 and continue FX Super One pre-orders [18] - The first version of the Manufacturing Management System is planned for release to ensure the first U.S. pre-production FX Super One is completed by year-end [21] - FX's second planned model, FX 4, will be showcased during the Los Angeles Auto Show [22]

Core Insights - Faraday Future Intelligent Electric Inc. has made a strategic investment in Qualigen Therapeutics Inc., which will be renamed AIxCrypto after the shareholder meeting on November 12, 2025 [1][2] - The investment amounts to over $41 million, with Faraday Future contributing approximately $30 million for a 55% stake, while founder Jia Yueting invests $4 million for a 7% stake [2] - AIxCrypto plans to launch new Web3 and cryptocurrency initiatives, including the public testing of BesTrade DeAI Agent and the release of the EAI RWA Utility token white paper by the end of November [2][3] Investment Details - Faraday Future's investment is led by Jia Yueting and includes participation from Binance Labs, Sequoia Capital, IDG, and Circle [1] - After the investment, Faraday Future and Jia Yueting will collectively hold about 62% of Qualigen Therapeutics [2] Business Strategy - AIxCrypto aims to achieve three key milestones by the end of 2025: 1. Expand the asset management scale of C10 Treasury to $50 million, enhancing its role as a core reserve asset in the Web3 ecosystem [2] 2. Accelerate the global growth of BesTrade DeAI Agent, establishing it as a top AI trading platform [3] 3. Launch a Crypto ecosystem token on leading exchanges, creating a sustainable on-chain value growth system [3]

Core Insights - Qualigen Therapeutics Inc. (QLGN) will rebrand to AIxCrypto after its shareholder meeting on November 12, 2025, and has set three core objectives for 2025 [1][2] Group 1: Business Strategy - QLGN has initiated a new Web3 and cryptocurrency business plan, with the public beta of BesTrade DeAI Agent set to launch at the end of November [1][2] - The first milestone aims to expand the C10 Treasury's asset management scale to $50 million, enhancing its role as a core reserve asset in the Web3 ecosystem [1] - As of October 17, 2023, QLGN's C10 Treasury has completed a $12 million allocation in cryptocurrency assets [1] Group 2: Product Development - The second milestone focuses on accelerating the global growth of BesTrade DeAI Agent, which is designed to optimize trading paths and returns, establishing itself as a leading AI trading platform [2] - The third milestone involves launching the Crypto ecosystem Token on leading exchanges, which will consist of C10 stablecoin and EAI+Crypto products, aiming to create a sustainable on-chain value growth system [2] Group 3: Investment Details - Faraday Future Intelligent Electric Inc. (FFAI), led by founder Jia Yueting, has made a strategic investment in QLGN, with the total investment expected to exceed $41 million, subject to shareholder approval [3] - FFAI invested approximately $30 million for about 55% ownership in QLGN, while Jia Yueting personally invested around $4 million for about 7% ownership [3] - Post-investment, FFAI and Jia Yueting will collectively hold approximately 62% of QLGN, with FFAI gaining significant board representation [3]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Click Holdings Limited (CLIK) is up 81% at $11.17 [3] - Avidity Biosciences, Inc. (RNA) is up 43% at $70.72 [3] - Dyne Therapeutics, Inc. (DYN) is up 37% at $23.58 [3] - Zenas BioPharma, Inc. (ZBIO) is up 21% at $29.00 [3] - ProPetro Holding Corp. (PUMP) is up 18% at $7.47 [3] - PepGen Inc. (PEPG) is up 17% at $5.35 [3] - Unusual Machines, Inc. (UMAC) is up 15% at $14.85 [3] - Semler Scientific, Inc. (SMLR) is up 14% at $27.32 [3] - ETHZilla Corporation (ETHZ) is up 13% at $20.51 [3] - Relmada Therapeutics, Inc. (RLMD) is up 13% at $2.38 [3] Premarket Losers - Smart Logistics Global Limited (SLGB) is down 37% at $3.21 [4] - MaxsMaking Inc. (MAMK) is down 22% at $4.08 [4] - Prenetics Global Limited (PRE) is down 14% at $14.40 [4] - United States Antimony Corporation (UAMY) is down 14% at $10.22 [4] - NeurAxis, Inc. (NRXS) is down 12% at $3.01 [4] - Obook Holdings Inc. (OWLS) is down 9% at $11.39 [4] - Qualigen Therapeutics, Inc. (QLGN) is down 9% at $3.30 [4] - Critical Metals Corp. (CRML) is down 8% at $13.70 [4] - Neuphoria Therapeutics Inc. (NEUP) is down 8% at $5.73 [4] - Beam Therapeutics Inc. (BEAM) is down 7% at $25.86 [4]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Qualigen Therapeutics, Inc. (QLGN) increased by 69% to $6.00 - Inhibrx Biosciences, Inc. (INBX) rose by 62% to $46.04 - MidWestOne Financial Group, Inc. (MOFG) gained 33% to $37.87 - Neuphoria Therapeutics Inc. (NEUP) up by 31% to $5.32 - Nextracker Inc. (NXT) increased by 13% to $102.44 - Avalon Holdings Corporation (AWX) rose by 11% to $2.98 - Beyond Meat, Inc. (BYND) up by 9% to $3.12 - SLM Corporation (SLM) increased by 8% to $29.00 - Reborn Coffee, Inc. (REBN) rose by 7% to $2.40 - Oriental Culture Holding LTD (OCG) increased by 5% to $3.55 [3] Premarket Losers - Picard Medical, Inc. (PMI) decreased by 70% to $3.89 - Fusemachines Inc. Common stock (FUSE) down by 17% to $3.29 - American Rebel Holdings, Inc. (AREB) fell by 16% to $3.14 - Armata Pharmaceuticals, Inc. (ARMP) down by 13% to $6.16 - Coya Therapeutics, Inc. (COYA) decreased by 13% to $6.01 - Deckers Outdoor Corporation (DECK) down by 12% to $90.00 - Safe & Green Holdings Corp. (SGBX) fell by 12% to $2.58 - Beasley Broadcast Group, Inc. (BBGI) decreased by 8% to $5.55 - Booz Allen Hamilton Holding Corporation (BAH) down by 7% to $92.73 - Brera Holdings PLC (SLMT) decreased by 6% to $10.67 [4]